Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTA-Directed PDT Triple Therapy for Wet AMD
NCT04075136Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2023
- Primary completion
- Nov 2024
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 4 trial of verteporfin, triamcinolone in exudative age-related macular degeneration, sponsored by Wake Forest University Health Sciences. Planned start Mar 2023; status: withdrawn.
02
Drugs
verteporfintriamcinolone
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT04075136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075136.